Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab Maintenance Post Cilta-cel in High Risk Relapsed Myeloma
NCT06947083Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- May 2025
- Primary completion
- Apr 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab in multiple myeloma (MM), sponsored by Moffitt Cancer Center. Started May 2025; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06947083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947083.